Full List Of Stories
AIM newcomer Cora Gold enters drilling agreement with Target
West Africa-focussed gold exploration company Cora Gold announced on Tuesday that its wholly-owned subsidiary Cora Gold Mali has entered into a contract with Target Drilling, to supply aircore, reverse circulation and diamond core drilling, focusing primarily on its flagship Sanankoro Gold Discovery in South Mali.
CloudCall raises £3.7m through two placings
Cloud-based software business CloudCall announced on Tuesday that it has raised approximately £3. 5m before expenses, by way of a placing of 2,457,774 new ordinary shares at 143. 5p.
Stratex offloads stake in Goldstone Resources
Gold exploration and development company Stratex announced the sale of its 13. 7% stake in Goldstone Resources to institutional investors on Tuesday, at a price of 1. 6p per share, for total cash consideration of £0. 55m.
Flowtech Fluidpower pumps out solid third quarter
Specialist technical fluid power products supplier Flowtech Fluidpower updated the market on its trading following its third quarter to 30 September on Tuesday, reporting that group revenue during the first nine months of the year was up 34. 4%.
RhythmOne expecting bumper first half amid acquisition spree
RhythmOne updated the market on its expected performance for the half year to 30 September on Tuesday, reporting revenues of between $112m and $114m, up from $67m in the first half of the 2017 financial year, which the company said was driven by “programmatic platform growth”.
Chi-Med trials with AstraZeneca show preliminary anti-tumour activity
Hutchison China MediTech - commonly known as Chi-Med - announced on Tuesday that both it and AstraZeneca presented preliminary safety and clinical activity data of savolitinib when given in combination with either Tagrisso (osimertinib) or Iressa (gefitinib) in two Phase Ib/II proof-of-concept trials conducted in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer with MET-amplification, who had progressed following first-line treatment with an EGFR inhibitor.
WANdisco Fusion now fully integrated with Microsoft Azure Data Box
‘Active data replication’ specialist WANdisco announced on Tuesday that its patented technology, WANdisco Fusion, is now fully integrated with Microsoft Azure Data Box, enabling Microsoft customers to transfer information from ‘Big Data’ applications to Microsoft Azure without the downtime and cost usually involved in bulk data transfer over the network.
Merlin mullered after missing forecasts as terror attacks weigh
Madame Tussauds and Legoland operator Merlin Entertainments disappointed with an update on its trading performance for the year to date, including the key summer period of July and August, taking the shine of new partnerships with Peppa Pig and Bear Grylls.
Asia report: Markets little changed as oil prices hold steady
Markets in Asia were little changed on Tuesday, with Japan closing higher for the 11th session in a row while oil prices maintained their strength.
Inspiration's 'rPAP Driver' receives CE marking
Medical technology supplier Inspiration Healthcare Group announced on Tuesday that the rPAP Driver unit, which it said is an integral part of the ‘Inspire rPAP’ neonatal resuscitation system, has been granted a CE mark and can now be sold throughout the EU and certain other territories around the world.
Virgin Money performing in line as credit behaviour remains 'stable'
Virgin Money updated the market on its third quarter trading on Tuesday, reporting that profitability, earnings and underlying return on tangible equity were all in line with expectations.
CMA condition satisfied in IP Group offer for Touchstone
IP Group’s offer for Touchstone Innovations was back on track on Tuesday morning, following a statement from the Competition and Markets Authority confirming that the competition watchdog had decided not to refer the merger to a Phase 2 investigation.
AstraZeneca's Imfinzi clears latest FDA regulatory hurdle
AstraZeneca and its global biologics research and development arm MedImmune announced on Tuesday that the US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab), for the treatment of patients with locally advanced (Stage III) unresectable non-small cell lung cancer (NSCLC) whose disease has not progressed following platinum-based chemoradiation therapy.